EYE · ASX

Nova Eye Medical Ltd (ASX:EYE)

AU$0.14

 -0.01 (-6.452%)
ASX:Live
20/12/2024 04:10:10 PM
HALO Ords HALO Consensus Value GROWTH AUS All-Consensus All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

EYE Overview

EYE Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Weak

Earnings

Very Strong

Growth

Earnings

Neutral

Dividends

Very Strong

Quality

Capital Efficiency

Strong

Balance Sheet

Very Strong

About EYE

Website

Nova Eye Medical Ltd

Telephone

N/A

Address

107 Rundle Street Kent Town, South Australia (SA) 5067

Description

Nova Eye Medical Ltd. engages in developing suite of novel ophthalmic treatment technologies. It operates through the following segments: Faster Growing (iTrack), Emerging (2RT), and Core Ophthalmic Mark (Lasers and Ultrasounds). The iTrack segment offers catheter device that dilates the ocular structures compromised by glaucoma. The 2RT segment includes patent-protected with significant lead on competition and a per-use recurring fee business model. The Lasers and Ultrasounds segment represents testimony to the strength of the Ellex brand and was driven by growth in sales of the high-margin Ellex Tango and Ellex Tango Reflex glaucoma lasers. The company was founded by Giuseppe Canala and Victor Previn in 1985 and is headquartered in Kent Town, Australia.

EYE Price Chart

Key Stats

Market Cap

AU$35.51M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

100%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.12 - 0.32

Trade Value (12mth)

AU$29,648.00

1 week

10.71%

1 month

-3.12%

YTD

-46.04%

1 year

32.65%

All time high

0.71

Key Fundamentals

EPS 3 yr Growth

46.10%

EBITDA Margin

-25.60%

Operating Cashflow

-$8m

Free Cash Flow Return

-32.00%

ROIC

-36.40%

Interest Coverage

-85.40

Quick Ratio

1.80

Other Data

Shares on Issue (Fully Dilluted)

229m

HALO Sector

Healthcare

Next Company Report Date

28-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

EYE Announcements

Latest Announcements

Date Announcements

17 December 24

Application for quotation of securities - EYE

×

Application for quotation of securities - EYE

28 November 24

Notification regarding unquoted securities - EYE

×

Notification regarding unquoted securities - EYE

28 November 24

Change of Director's Interest Notice

×

Change of Director's Interest Notice

27 November 24

Notification of cessation of securities - EYE

×

Notification of cessation of securities - EYE

27 November 24

Change of Director's Interest Notice

×

Change of Director's Interest Notice

21 November 24

2024 AGM presentation

×

2024 AGM presentation

21 November 24

2024 AGM Voting Results

×

2024 AGM Voting Results

31 October 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

18 October 24

Notice of AGM

×

Notice of AGM

27 September 24

2024 AGM date and closing date for Director Nominations

×

2024 AGM date and closing date for Director Nominations

26 August 24

Appendix 4E and Annual Report

×

Appendix 4E and Annual Report

26 August 24

Full Year Financial Results

×

Full Year Financial Results

26 August 24

Investor Presentation 30 June 2024 Results

×

Investor Presentation 30 June 2024 Results

26 August 24

Appendix 4G

×

Appendix 4G

23 August 24

Notification of cessation of securities - EYE

×

Notification of cessation of securities - EYE

02 August 24

Application for quotation of securities - EYE

×

Application for quotation of securities - EYE

02 August 24

Notification regarding unquoted securities - EYE

×

Notification regarding unquoted securities - EYE

08 July 24

Record Sales Results

×

Record Sales Results

08 July 24

Presentation FY24 Sales

×

Presentation FY24 Sales

31 May 24

USA Medicare Update

×

USA Medicare Update

10 May 24

Notification regarding unquoted securities - EYE

×

Notification regarding unquoted securities - EYE

10 May 24

Application for quotation of securities - EYE

×

Application for quotation of securities - EYE

19 March 24

Change of Director's Interest Notice

×

Change of Director's Interest Notice

19 March 24

Change of Director's Interest Notice

×

Change of Director's Interest Notice

19 March 24

Change of Director's Interest Notice

×

Change of Director's Interest Notice

EYE Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.05 -0.10 -0.04 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.05 -0.10 -0.04 Lock Lock Lock
     Growth % Lock Lock Lock Lock -71.2 -89.1 54.9 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.05 -0.04 -0.03 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.03 -0.04 -0.04 Lock Lock Lock
     Growth % Lock Lock Lock Lock -150.9 25.2 28.8 Lock Lock Lock
     Yield % Lock Lock Lock Lock -18.0 -16.9 -17.7 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.20 0.12 0.09 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.08 0.05 0.04 Lock Lock Lock
     Growth % Lock Lock Lock Lock -47.4 -39.0 -12.0 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 149 160 204 Lock Lock Lock
Basic m Lock Lock Lock Lock 149 160 204 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 13 17 23 Lock Lock Lock
     Growth % Lock Lock Lock Lock -0.1 27.3 37.0 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 9 13 14 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -1 1 5 Lock Lock Lock
     Growth % Lock Lock Lock Lock -143.3 210.1 544.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock -5.7 4.9 23.3 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 106 95 77 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -8 -10 -6 Lock Lock Lock
     Growth % Lock Lock Lock Lock -133.9 -18.4 37.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock -60.3 -56.1 -25.6 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 2 2 3 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -10 -12 -9 Lock Lock Lock
     Growth % Lock Lock Lock Lock -99.0 -19.9 24.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock -73.9 -69.6 -38.4 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -8 -17 -9 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 -2 0 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -7 -15 -9 Lock Lock Lock
     Growth % Lock Lock Lock Lock -72.1 -104.0 42.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock -56.0 -89.8 -37.7 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -5 -7 -8 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 6 1 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -5 -1 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 0 7 7 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -5 -7 -8 Lock Lock Lock
     Growth % Lock Lock Lock Lock 63.7 -45.0 -13.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock -0.4 -0.4 -0.3 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 8 7 6 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 37 30 30 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 1 1 3 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -6 -6 -3 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 6 7 9 Lock Lock Lock
Equity $m Lock Lock Lock Lock 30 23 21 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 32 24 24 Lock Lock Lock
     Growth % Lock Lock Lock Lock -14.3 -24.3 0.5 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -20.5 -50.4 -29.4 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -24.7 -65.9 -41.2 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -27.7 -41.5 -36.3 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -21.8 -54.7 -36.4 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -13.6 -24.1 -32.0 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock -126.1 -176.9 -85.4 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.8 0.6 0.5 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -19.9 -25.4 -13.1 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 4.0 2.3 2.6 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 3.1 1.7 1.8 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 51.3 50.8 41.7 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -121.2 -107.1 -136.1 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 2.9 5.0 6.5 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 4.4 4.4 4.4 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 1.1 2.0 2.6 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 18.0 25.3 15.3 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.4 0.6 0.8 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.4 0.6 0.8 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -58.4 -99.9 -37.7 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -21.3 -56.0 -29.4 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -20.5 -50.4 -29.4 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.2 1.3 1.4 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -24.7 -65.9 -41.2 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -24.7 -65.9 -41.2 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 83.1 82.8 82.5 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 125.5 73.7 56.2 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 208.6 156.5 138.7 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 56.9 74.5 78.2 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 151.7 82.0 60.5 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

100%

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

EYE Shortsell

Frequently Asked Questions

The current share price of Nova Eye Medical Ltd (EYE:ASX) is AU$0.14.
The 52-week high share price for Nova Eye Medical Ltd (EYE:ASX) is AU$0.32.
The 52-week low share price for Nova Eye Medical Ltd (EYE:ASX)? is AU$0.12.
Nova Eye Medical Ltd (EYE:ASX) does not pay a dividend.
The last dividend payment of Nova Eye Medical Ltd (EYE:ASX) is AU$0.43.
Nova Eye Medical Ltd (EYE:ASX) has a franking level of 100.0%.
Nova Eye Medical Ltd (EYE:ASX) is classified in the Healthcare.
The current P/E ratio for Nova Eye Medical Ltd (EYE:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.